By Kate O’Rourke
Originally published by our sister publication Clinical Oncology News
Patients with acute myeloid leukemia (AML) who are older and fit who get pretreated with a 10-day regimen of decitabine (Dacogen, Otsuka) before an allogeneic hematopoietic stem cell transplant have similar overall survival (OS) and fewer side effects than those who receive conventional intensive chemotherapy, according to a new study. These findings, from a phase 3 trial, were presented at the 2022